All In Biotech

NDA 206334 · Melinta Therap

Orbactiv

Oritavancin Diphosphate · Intravenous · Lipoglycopeptide Antibacterial

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jan 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 6, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

7

2 Phase 3, 0 recruiting

FAERS reports

920

352 serious, 32 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 15, 2026.

ORBACTIV is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Acute Bacterial Skin and Skin Structure Infections ORBACTIV ® (oritavancin) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus dysgalactiae , Streptococcus anginosus group (includes S. anginosus , S. intermedius , and S. constellatus ), and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Oritavancin is an antibacterial drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ORBACTIV · ORITAVANCIN DIPHOSPHATE EQ 400MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oritavancin Diphosphate" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use175
  • pruritus165
  • urticaria105
  • chills90
  • rash86
  • back pain83
  • dyspnoea81
  • nausea68
  • infusion related reaction62
  • erythema58
  • chest pain56
  • drug ineffective49

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
201547
2016159
2017182
2018141
201982
202073
202141
202267
202338
202436
202530
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orbactiv (Oritavancin Diphosphate)

2024 spending

$280K

Beneficiaries

46

83 claims

Per beneficiary

$6,092

$34.16 per unit

View as table
YearSpending
2020$719,116
2021$1,008,342
2022$642,766
2023$230,797
2024$280,232

Part B: Orbactiv (Oritavancin Diphosphate) · HCPCS J2407

2024 spending

$2.0M

Beneficiaries

336

609 claims

Per beneficiary

$5,937

2024 ASP limit $27.77 per unit

View as table
YearSpending
2020$5,087,076
2021$4,386,715
2022$3,553,178
2023$1,767,869
2024$1,994,666

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Melinta Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.